- Home
- SILO vs AIM Comparison
SILO vs AIM Comparison
Compare SILO & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILO
- AIM
- Stock Information
- Founded
- SILO 2010
- AIM 1966
- Country
- SILO United States
- AIM United States
- Employees
- SILO N/A
- AIM N/A
- Industry
- SILO Apparel
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SILO Consumer Discretionary
- AIM Health Care
- Exchange
- SILO Nasdaq
- AIM Nasdaq
- Market Cap
- SILO 8.8M
- AIM 8.8M
- IPO Year
- SILO N/A
- AIM N/A
- Fundamental
- Price
- SILO $1.08
- AIM $0.12
- Analyst Decision
- SILO
- AIM Strong Buy
- Analyst Count
- SILO 0
- AIM 2
- Target Price
- SILO N/A
- AIM $2.75
- AVG Volume (30 Days)
- SILO 139.6K
- AIM 476.8K
- Earning Date
- SILO 05-12-2025
- AIM 03-27-2025
- Dividend Yield
- SILO N/A
- AIM N/A
- EPS Growth
- SILO N/A
- AIM N/A
- EPS
- SILO N/A
- AIM N/A
- Revenue
- SILO $72,102.00
- AIM $170,000.00
- Revenue This Year
- SILO $1.86
- AIM N/A
- Revenue Next Year
- SILO N/A
- AIM $1,693.10
- P/E Ratio
- SILO N/A
- AIM N/A
- Revenue Growth
- SILO N/A
- AIM N/A
- 52 Week Low
- SILO $0.77
- AIM $0.11
- 52 Week High
- SILO $4.50
- AIM $0.62
- Technical
- Relative Strength Index (RSI)
- SILO 28.08
- AIM 42.13
- Support Level
- SILO $1.20
- AIM $0.11
- Resistance Level
- SILO $1.39
- AIM $0.16
- Average True Range (ATR)
- SILO 0.09
- AIM 0.01
- MACD
- SILO -0.02
- AIM 0.00
- Stochastic Oscillator
- SILO 0.00
- AIM 5.00
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.